Abstract
This study aimed to investigate the expressions, clinical significances, roles, and mechanism of action of MRCCAT1 in glioma. The expression of MRCCAT1 in 103 glioma tissues with different grades and 21 normal brain tissues was measured by qPCR. The prognostic value of MRCCAT1 was investigated by Kaplan-Meier survival analysis. The biological roles of MRCCAT1 on glioma cell proliferation were assessed by Glo cell viability assays and ethynyl deoxyuridine incorporation assays. The roles of MRCCAT1 on glioma cell migration were evaluated by transwell assays. The effects of MRCCAT1 on p38-MAPK signaling were assessed by Western blot. MRCCAT1 is upregulated in glioma tissues and positively associated with glioma grades. Increased expression of MRCCAT1 confers poor prognosis of glioma patients independent of glioma grades. Ectopic expression of MRCCAT1 promotes glioma cell proliferation and migration. Knockdown of MRCCAT1 inhibits glioma cell proliferation and migration. Mechanistically, we found that MRCCAT1 activates p38-MAPK signaling in glioma. MRCCAT1 is upregulated in glioma. Increased expression of MRCCAT1 predicts poor outcome of glioma patients. MRCCAT1 promotes glioma cell proliferation and migration via activating p38-MAPK signaling. MRCCAT1 may be a potential prognostic biomarker and therapeutic target for glioma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European review for medical and pharmacological sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
